Forbes June 5, 2024
Dave Wessner

An FDA advisory committee recommended the development of a new Covid-19

vaccine at its meeting on Wednesday. According to the panel, vaccine manufacturers should design updated vaccines to target the JN.1 variant of SARS-CoV-2. Ideally, these updated vaccines will be available in the fall.

The Vaccines and Related Biological Products Advisory Committee of the FDA evaluated the effectiveness of the current vaccines and discussed the need for a new vaccine formulation. Representatives from Moderna, Pfizer-BioNtech, and Novavax presented data about the protection offered by current vaccines against emerging variants and the potential benefits of vaccines specifically targeting these new strains.

Following the presentations and a period of public comment, the panel voted unanimously to recommend that the 2024-2025 Covid-19 vaccine...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
Califf: Do right by AI and patients
Key takeaways from Marty Makary’s FDA confirmation hearing
‘He needs to do much more’: RFK Jr.'s measles response under scrutiny
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy

Share This Article